Alcidion Group Limited

ASX:ALC Stock Report

Market Cap: AU$77.9m

Alcidion Group Valuation

Is ALC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ALC (A$0.06) is trading below our estimate of fair value (A$0.18)

Significantly Below Fair Value: ALC is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALC?

Key metric: As ALC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ALC. This is calculated by dividing ALC's market cap by their current revenue.
What is ALC's PS Ratio?
PS Ratio2.1x
SalesAU$37.06m
Market CapAU$77.89m

Price to Sales Ratio vs Peers

How does ALC's PS Ratio compare to its peers?

The above table shows the PS ratio for ALC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.4x
M7T Mach7 Technologies
3x18.1%AU$88.1m
BMT Beamtree Holdings
2.5x21.9%AU$69.5m
CGS Cogstate
2.6x10.9%AU$171.8m
MDR MedAdvisor
1.3x13.4%AU$162.6m
ALC Alcidion Group
2.1x8.2%AU$77.9m

Price-To-Sales vs Peers: ALC is good value based on its Price-To-Sales Ratio (2.1x) compared to the peer average (2.4x).

Price to Sales Ratio vs Industry

How does ALC's PS Ratio compare vs other companies in the AU Healthcare Services Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
MDR MedAdvisor
1.3x13.4%US$105.00m
DOC Doctor Care Anywhere Group
0.3x6.3%US$14.92m
IME ImExHS
0.7x20.5%US$11.93m
VFX Visionflex Group
1.9xn/aUS$8.48m
ALC 2.1xIndustry Avg. 2.9xNo. of Companies7PS0816243240+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ALC is good value based on its Price-To-Sales Ratio (2.1x) compared to the Global Healthcare Services industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is ALC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.1x
Fair PS Ratio3.2x

Price-To-Sales vs Fair Ratio: ALC is good value based on its Price-To-Sales Ratio (2.1x) compared to the estimated Fair Price-To-Sales Ratio (3.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ALC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.058
AU$0.083
+43.7%
11.3%AU$0.09AU$0.07n/a3
Nov ’25AU$0.053
AU$0.083
+57.2%
11.3%AU$0.09AU$0.07n/a3
Oct ’25AU$0.06
AU$0.083
+38.9%
11.3%AU$0.09AU$0.07n/a3
Sep ’25AU$0.072
AU$0.087
+20.4%
5.4%AU$0.09AU$0.08n/a3
Aug ’25AU$0.073
AU$0.093
+27.8%
10.1%AU$0.10AU$0.08n/a3
Jul ’25AU$0.051
AU$0.08
+56.9%
27.0%AU$0.10AU$0.05n/a3
Jun ’25AU$0.058
AU$0.08
+37.9%
27.0%AU$0.10AU$0.05n/a3
May ’25AU$0.052
AU$0.08
+53.8%
27.0%AU$0.10AU$0.05n/a3
Apr ’25AU$0.051
AU$0.077
+50.3%
26.8%AU$0.10AU$0.05n/a3
Mar ’25AU$0.046
AU$0.087
+88.4%
10.9%AU$0.10AU$0.08n/a3
Feb ’25AU$0.052
AU$0.097
+85.9%
12.9%AU$0.11AU$0.08n/a3
Jan ’25AU$0.075
AU$0.11
+46.7%
19.6%AU$0.13AU$0.08n/a3
Dec ’24AU$0.074
AU$0.11
+48.6%
19.6%AU$0.13AU$0.08n/a3
Nov ’24AU$0.07
AU$0.14
+95.2%
12.4%AU$0.16AU$0.12AU$0.0533
Aug ’24AU$0.13
AU$0.16
+30.7%
7.6%AU$0.18AU$0.15AU$0.0733
Jul ’24AU$0.095
AU$0.19
+100.0%
5.3%AU$0.20AU$0.18AU$0.0512
Jun ’24AU$0.094
AU$0.19
+102.1%
5.3%AU$0.20AU$0.18AU$0.0582
May ’24AU$0.097
AU$0.19
+95.9%
5.3%AU$0.20AU$0.18AU$0.0522
Feb ’24AU$0.15
AU$0.20
+36.7%
2.4%AU$0.21AU$0.20AU$0.0522
Jan ’24AU$0.14
AU$0.20
+41.4%
2.4%AU$0.21AU$0.20AU$0.0752
Dec ’23AU$0.17
AU$0.20
+14.7%
2.6%AU$0.20AU$0.19AU$0.0742

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Cogstate

AU$171.8m

A neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research.

CGS

AU$0.99

7D

4.7%

1Y

-31.4%

SDI

AU$127.8m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.08

7D

5.4%

1Y

29.5%

Doctor Care Anywhere Group

AU$23.1m

Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.

DOC

AU$0.063

7D

-10.0%

1Y

26.0%